High throughput screening (HTS) relies on liquid handling devices, robotics, plate readers, and data processing software to automatically test a large number of biological, genetic, chemical, or pharmacological samples.
Found circulating in peripheral blood, scientists use cell-free DNA (cfDNA) to assess genetic abnormalities, infections, cancer, transplant rejection, and cardiovascular disease.